Author Interviews, Diabetes, Orthopedics / 08.08.2016
New Anti-Diabetic Compound May Avoid Bone Loss Seen With Current Medications
MedicalResearch.com Interview with:
[caption id="attachment_26825" align="alignleft" width="133"]
Dr. Patrick Griffin[/caption]
Patrick Griffin, PhD
Professor
Department of Molecular Therapeutics
The Scripps Research Institute Florida Campus
MedicalResearch.com: What is the background for this study?
Response: Over the past decade, our laboratory and that of TSRI Associate Professor Theodore Kamenecka, have focused on molecules that increase sensitivity to insulin. Using newly discovered information, we have made significant advances in developing a family of drug candidates that target a receptor known as peroxisome proliferator-activated receptors gamma (PPARγ), a key regulator of stem cells controlling bone formation and bone resorption and a master regulator of fat.
Dr. Patrick Griffin[/caption]
Patrick Griffin, PhD
Professor
Department of Molecular Therapeutics
The Scripps Research Institute Florida Campus
MedicalResearch.com: What is the background for this study?
Response: Over the past decade, our laboratory and that of TSRI Associate Professor Theodore Kamenecka, have focused on molecules that increase sensitivity to insulin. Using newly discovered information, we have made significant advances in developing a family of drug candidates that target a receptor known as peroxisome proliferator-activated receptors gamma (PPARγ), a key regulator of stem cells controlling bone formation and bone resorption and a master regulator of fat.




















